Shilpa Medicare Ltd

Shilpa Medicare Secures Third Major International Mandate 🚀

- Shilpa Medicare updated its disclosure to align with an upcoming high-impact journal publication, clarifying the therapy targets autoimmune or alloimmune disorders.

- The company entered a strategic partnership with Switzerland-based NXI Therapeutics AG for development, manufacturing, and supply of a new chemical entity (NCE).

- Shilpa will provide comprehensive support including CMC development, process scale-up, GMP clinical supply, and long-term commercial manufacturing.

- This marks Shilpa's third major international mandate in recent months, enhancing its role in high-value biotech pipelines.

- The agreement includes milestone-linked expansion potential and may evolve into a multi-year commercial supply relationship based on clinical and regulatory success.